TNF Pharmaceuticals (TNFA) files notice of delayed Q2 2025 10-Q filing

Rhea-AI Filing Summary

TNF Pharmaceuticals, Inc. filed a notice that it will not submit its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 on time. The company states it needs additional time to complete and finalize the financial statements required for this report. It expects to file the Form 10-Q on or before the fifth calendar day after the original due date, relying on the automatic extension provided under SEC Rule 12b-25.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: June 30, 2025

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended:

___________________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I – REGISTRANT INFORMATION

TNF Pharmaceuticals, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

1185 Avenue of the Americas. Suite 249

Address of Principal Executive Office (Street and Number)

New York, NY 10036

City, State and Zip Code

PART II – RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

TNF Pharmaceuticals, Inc. (the “Company”) is unable to file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 (the “Form 10-Q”), because the Company requires additional time to complete and finalize its financial statements required to be included in the Form 10-Q. The Company currently anticipates that the Form 10-Q will be filed on or before the fifth calendar day following the prescribed due date. 

PART IV – OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Joshua Silverman		856		848-8698
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
	Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

TNF Pharmaceuticals, Inc.

(Name of registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 14, 2025		By:	/s/ Joshua Silverman
			Name:	Joshua Silverman
			Title:	Director

3

FAQ

Why did TNF Pharmaceuticals (TNFA) file a Form 12b-25?

TNF Pharmaceuticals filed Form 12b-25 because it could not file its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 without unreasonable effort and expense and needs more time to complete and finalize its financial statements.

Which report is TNF Pharmaceuticals (TNFA) delaying with this NT 10-Q?

The company is delaying its Quarterly Report on Form 10-Q for the six months ended June 30, 2025.

When does TNF Pharmaceuticals expect to file the delayed Form 10-Q?

The company currently anticipates filing the Form 10-Q on or before the fifth calendar day following the prescribed due date.

What reason does TNF Pharmaceuticals give for the late Form 10-Q filing?

TNF Pharmaceuticals explains that it requires additional time to complete and finalize the financial statements that must be included in the Form 10-Q, and that filing on time would require unreasonable effort and expense.

Who signed the TNF Pharmaceuticals Form 12b-25 notice?

The notification was signed on behalf of TNF Pharmaceuticals, Inc. by Joshua Silverman, who is identified as a Director.

What period does the delayed TNF Pharmaceuticals Form 10-Q cover?

The delayed Form 10-Q covers the six months ended June 30, 2025.